Success Story: Tumor Biology Research Advancing Cancer Immunotherapy Wins NIW Approval With Direct Premium Processing
Client’s Testimonial:
"Thank you so much again for your support with I-140 application! I am really glad to hear that it is approved.”
On June 12th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for an Assistant Professor in the Field of Tumor Biology (Approval Notice).
General Field: Tumor Biology
Position at the Time of Case Filing: Assistant Professor
Country of Origin: Japan
State of Residence at the Time of Filing: New York
Approval Notice Date: June 12th, 2026
Processing Time: 1 month, 27 days (Premium Processing Requested)
Case Summary:
This NIW case was not built around tumor biology in the abstract. It was built around a specific biomedical challenge with direct public health consequences: how to make immunotherapy more effective for small-cell lung cancer and other tumors that resist immune-based treatment. The petition was filed with direct premium processing at the time of filing.
North America Immigration Law Group presented the petition by showing that the client’s work connects several high-impact areas under one coherent scientific mission. The client holds a Ph.D. in internal medicine and, at the time of filing, was employed as an assistant professor in a U.S.-based academic research setting. His proposed endeavor focused on applying CRISPR-based functional screening, next-generation sequencing technologies, and in vivo tumor models to uncover molecular vulnerabilities that activate tumor-intrinsic immune responses. The petition framed this work as a focused contribution to cancer research: identifying why certain tumors remain immunologically resistant and how those tumors may be made more responsive to immunotherapy.
A key part of the filing was showing that the client’s research had practical relevance beyond laboratory discovery. His work addresses “cold” tumors, which often have limited immune cell infiltration and respond poorly to existing immunotherapy approaches. By identifying molecular targets that can activate innate immune responses within tumor cells, his research supports the development of next-generation cancer treatment strategies. The petition connected this work to U.S. priorities in cancer care, precision oncology, biotechnology, and biomedical innovation, especially given the national burden of lung cancer and the urgent need for improved therapies for treatment-resistant cancers.
A strong feature of the filing was the depth and quality of the client’s record. We documented 15 peer-reviewed journal articles, including 5 first-authored articles and 3 co-first-authored articles, 7 conference abstracts, including 4 first-authored abstracts, 928 citations, at least 16 completed peer reviews, and research support from the National Cancer Institute (NCI). The petition also showed that multiple papers ranked among the top 1%, top 10%, or top 20% most-cited Clinical Medicine articles for their publication years.
These metrics were not presented as numbers alone. The petition explained that the client’s publication record, citation history, and percentile rankings reflected sustained independent reliance by other researchers. His work had been used by other scientists studying RNA helicases, tumor immune response regulation, cGAS-STING pathway activation, immune checkpoint resistance, and tumor growth suppression. That independent reliance mattered because it showed not just scholarly productivity, but actual influence on how the field investigates cancer immunotherapy resistance and tumor-intrinsic immune activation.
The filing also emphasized the client’s service as a reviewer for respected journals in cancer biology, genetics, precision oncology, molecular cancer research, and related biomedical disciplines. This helped show that the field trusted his judgment to evaluate the work of other researchers. Together with his funded research, expert testimonial evidence, highly cited publications, and current academic role, this review service reinforced that the client was well-positioned to continue advancing the proposed endeavor.
We were proud to help secure this I-140 NIW approval for a tumor biology researcher whose work strengthens the scientific foundation for improved cancer immunotherapy, precision oncology, and targeted treatment strategies in the United States.